The field of research ethics, once focused on protecting vulnerable subjects from harm, has evolved. A cultural emphasis on individual liberty, exemplified by the "right-to-try" movement, has created a new ethos where patients demand access to experimental treatments, even with high risks.

The Huntington's community isn't demanding carte blanche approval for uniQure's drug. They are advocating for an accelerated pathway that grants access to patients who understand the risks, allowing for continued data collection without a five-year sham trial that could make them ineligible for treatment later.

The rise of online communities self-experimenting with peptides is a grassroots movement driven by a desire to take health into their own hands. It signals growing impatience with the slow, expensive, and restrictive traditional pathways of FDA-approved drug development.

The 'Right to Try' Act fundamentally changed end-of-life care dynamics. For patients who have failed standard treatments, it transfers significant liability from the physician to the patient, empowering doctors to pursue innovative, evidence-backed therapies without the same legal risk.

The FDA's demand for a randomized controlled trial for a Huntington's drug is ethically compromised. Patients in the placebo group would likely progress beyond the specific disease stage (TFC 9-13) required for treatment, making them permanently ineligible for the drug if it's eventually approved.

As AI allows any patient to generate well-reasoned, personalized treatment plans, the medical system will face pressure to evolve beyond rigid standards. This will necessitate reforms around liability, data access, and a patient's "right to try" non-standard treatments that are demonstrably well-researched via AI.

The fastest, cheapest path to drug approval involves showing a small survival benefit in terminally ill patients. This economic reality disincentivizes the longer, more complex trials required for early-stage treatments that could offer a cure.

As AI models become adept at identifying novel or experimental treatments for individuals, it will create mounting pressure on the medical regulatory system. Patients, armed with compelling, AI-generated arguments for a specific therapy, will increasingly challenge the gates kept by establishments, potentially forcing an evolution of the social contract around access to unproven medicines ('right to try').

Unlike "Right to Try" for the sick, "challenge trials" involve intentionally infecting healthy volunteers to accelerate cure development. This raises profound ethical questions, with some seeing it as heroic sacrifice and others viewing the act of deliberately harming a healthy person as a line that shouldn't be crossed.